Join

Compare · ABBV vs ANIP

ABBV vs ANIP

Side-by-side comparison of AbbVie Inc. (ABBV) and ANI Pharmaceuticals Inc. (ANIP): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ABBV and ANIP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • ABBV is the larger of the two at $401.47B, about 220.4x ANIP ($1.82B).
  • Over the past year, ABBV is up 18.6% and ANIP is up 28.8% - ANIP leads by 10.2 points.
  • ABBV has been more active in the news (10 items in the past 4 weeks vs 2 for ANIP).
  • ABBV has more recent analyst coverage (25 ratings vs 11 for ANIP).
PerformanceABBV+18.64%ANIP+28.83%
2025-06-09+0.00%2026-06-08
MetricABBVANIP
Company
AbbVie Inc.
ANI Pharmaceuticals Inc.
Price
$224.28-1.24%
$81.41+0.44%
Market cap
$401.47B
$1.82B
1M return
+10.67%
-3.18%
1Y return
+18.64%
+28.83%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2012
News (4w)
10
2
Recent ratings
25
11
ABBV

AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

ANIP

ANI Pharmaceuticals Inc.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.

Latest ABBV

Latest ANIP